

Diagnosis and treatment of FHL - first patient with complete perforin deficiency diagnosed in Czech Republic

**R. Formánková, E. Mejstříková, R. Špíšek, O. Hrušák,
P. Sedláček, P. Keslová, V. Vávra, A. Šedivá, J Bartůňková,
J. Starý**

**Department of Pediatric Hematology and Oncology
Department of Immunology
University Hospital Motol, Prague**

Introduction

HLH – uncontrolled proliferation of T lymphocytes and macrophages

- familial (primary) hemophagocytic lymphohistiocytosis (FHL)
- secondary HLH (systemic infection, malignancy or syst. AI)

FHL – fatal inherited disease of infancy and early childhood
1:50 000 live born

- the only chance for cure – allo stem cell transplantation (SCT)
- 30% patients – mutation in perforin gene (10q21.3-22)
perforin deficiency in T-lymphocytes and NK cells
- defect in NK and Tcells cytotoxicity

Family and past medical history

❖ girl, 1 month old at diagnosis of FHL

FH: negative

PMH: from 2nd pregnancy

delivery in 38th week, 2750g/47 cm,
adaptation after delivery normal


❖ first 4 weeks of life without complications

Onset of the disease

- ❖ 29th day of life
 - fever
 - hepatomegaly (+5cm), splenomegaly (+5cm)
 - WBC $14 \times 10^9/l$, Hb 97g/l, Plt $55..33 \times 10^9/l$
 - coagulopathy
- ❖ admission to pediatric department, therapy with ATB
 - bone marrow aspiration – susp. ALL
- ❖ 30th day of life - transfer to our hospital




Clinical, laboratory and histopathological findings



- ❖ hepatosplenomegaly
- ❖ fever
- ❖ cytopenia - anemia, thrombocytopenia ($\cdot 16 \times 10^9/l$)
- ❖ **↑** triglycerides (3,29 mmol/l)
- ❖ **↓** fibrinogen (0,89 g/l)
- ❖ **↑↑** ferritin (7816 .. 40640 $\mu\text{g/l}$)
- ❖ hemophagocytosis in bone marrow aspiration
- ❖ no CNS involvement

Perforin expression - FC

Flow cytometric analysis. Dot plot.




perforin deficiency

normal perforin expression in control patient


HLA DR expression

HLA DR expression on CD8+3+ T cells at
A diagnosis in peripheral blood (88%) and
B after HLH 2004 treatment in remission prior to BMT



Cytotoxic assay

Cytotoxic activity of T-lymphoblasts generated from T-cells
Target cells: L1210 cells deficient in FAS expression



Defective cytotoxic activity of patient's lymphoblasts


Therapy – HLH 2004

- ❖ 4.8.2004 day of admission
- ❖ 5.8.2004 VP-16, dexamethasone, cyclosporine A
- ❖ non identical sibling → MUD search initiated
- ❖ 5.8. sepsis (Acinetobacter)
- ❖ 6.8. progression of hepatosplenomegaly
respiratory insufficiency
- ❖ 6.8.-11.8. arteficial ventilatory support
- ❖ 18.8. sepsis (Pseud. aeruginosa, Staph. haemolyticus)
- ❖ 8.10. admission to BMT unit for unrelated SCT

Stem cell transplantation

- ❖ 19.10.2004 (aged 3,5 months)
- ❖ donor: MUD, 9/10 (Cw), PBSC (CD34+ 8×10^6 /kg)
- ❖ conditioning: Busulfan, VP-16, Cyclophosphamide, ATG
- ❖ GVHD prophylaxis: Cyclosporine A, Methotrexate
- ❖ engraftment: ANC D+15, Plt D+19
- ❖ GVHD: none
- ❖ complications: febrile neutropenia D+2, nephropathy
- ❖ discharge from BMT unit: D+85 (aged 6 months)

Hemopoietic chimerism



D+180 after SCT

- ❖ no GVHD, no signs of FHL reactivation
- ❖ stable MC in peripheral blood and MC in T-lymphocytes (75% of allogeneic hemopoiesis)
- ➔ might be curative for FHL





**Thank you
for attention**